The first practice parameters published on amyotrophic lateral sclerosis (ALS) by the American Academy of Neurology (AAN) enhanced the care of people with this condition. These guidelines have now been updated on the basis of new evidence and will continue to provide the impetus for new research and better care; however, harmonization of the AAN and European guidelines is desirable.
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Miller, R. G. et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 52, 1311–1323 (1999).
Andersen, P. M. et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur. J. Neurol. 12, 921–938 (2005).
Heffernan, C. et al. Nutritional management in MND/ALS patients: an evidence based review. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5, 72–83 (2004).
Heffernan, C. et al. Management of respiration in MND/ALS patients: an evidence based review. Amyotroph. Lateral Scler. 7, 5–15 (2006).
Miller, R. G. et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73, 1218–1226 (2009).
Miller, R. G. et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73, 1227–1233 (2009).
Bensimon, G. et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS Study. Brain 132, 156–171 (2009).
Landwehrmeyer, G. B. et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol. 62, 262–272 (2007).
Bourke, S. C. et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 5, 140–147 (2006).
P. N. Leigh has received honoraria from GlaxoSmithKline, and Sanofi-aventis for lectures and honoraria from Acceleron Pharma, GlaxoSmithKline, NeuroNova, Sanofi-aventis, and Trophos for consulting. He has also received research funding from GlaxoSmithKline, Sanofi-aventis and Trophos. L. C. Wijesekera declares no competing interests.
About this article
Cholesterol secosterol aldehyde adduction and aggregation of Cu,Zn-superoxide dismutase: Potential implications in ALS
Redox Biology (2018)
A progressive translational mouse model of human valosin-containing protein disease: TheVCPR155H/+mouse
Muscle & Nerve (2013)
Neurochemistry International (2012)
The Multiple Faces of Valosin-Containing Protein-Associated Diseases: Inclusion Body Myopathy with Paget’s Disease of Bone, Frontotemporal Dementia, and Amyotrophic Lateral Sclerosis
Journal of Molecular Neuroscience (2011)